424870.KQ ImmuneOncia
- Market cap
- KRW 230B
- P/E
- -
- P/B
- 2.29x
- ROE
- -19.0%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 424870.KQ undervalued?
Graham numberThe Graham number of ImmuneOncia cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ImmuneOncia fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-19.0%), below 10%.
ROA 0/1
Return on assets (-18.1%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-372.4%) is below the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 75.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 3.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.3x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
ImmuneOncia stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ImmuneOncia
ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, whic…
Full company profileImmuneOncia financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ImmuneOncia annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 35.9M | 7.73B | 110M | 655M | 111M | - |
| Gross Profit | 35.9M | 7.73B | 110M | 655M | 111M | - |
| Operating Income | -11.9B | -15.1B | -11.8B | -12.6B | -28.0B | -20.1B |
| EBITDA | - | -2.37B | 9.90B | -4.63B | -26.5B | -18.3B |
| Net Income | -60.5B | -3.49B | 8.86B | -5.69B | -27.4B | -19.0B |
| EPS | -829 | -44 | 113 | -72 | -342 | -209 |
| Balance Sheet | ||||||
| Total Assets | 51.1B | 35.7B | 33.8B | 26.2B | 33.1B | 105B |
| Total Liabilities | 111B | 88.1B | 68.0B | 6.77B | 4.73B | 4.86B |
| Shareholders' Equity | -59.5B | -52.4B | -34.2B | 19.4B | 28.4B | 100B |
| Cash & Short-term Investments | 36.3B | 26.7B | 21.0B | 8.23B | 8.24B | 83.1B |
| Cash Flow | ||||||
| Operating Cash Flow | -1.98B | -15.3B | -8.34B | -14.7B | -22.8B | -23.0B |
| Capital Expenditure | 106M | 88.6M | 428M | 139M | 468M | 171M |
| Free Cash Flow | -2.08B | -15.4B | -8.77B | -14.8B | -23.2B | -23.2B |
| Ratios | ||||||
| ROE | - | - | - | -29.3% | -96.3% | -19.0% |
| ROA | -118.4% | -9.8% | 26.2% | -21.7% | -82.6% | -18.1% |
| Net Profit Margin | -168,275.2% | -45.2% | 8,058.2% | -868.9% | -24,605.1% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ImmuneOncia dividends
ImmuneOncia has not paid dividends in the last 6 fiscal years.
Who owns ImmuneOncia
- Insiders 56.49%
- Institutions 0.86%
- Public & others 42.65%
- Shares outstanding 91.3M
- Free float 31.1M
ImmuneOncia company profile
- Company name
- ImmuneOncia
- Ticker
- 424870.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 25 Tapsil-ro 35beon-gil, Yongin-si, South Korea, 17084
- Phone
- 82 3 1306 8177
- Website
- immuneoncia.com
About ImmuneOncia
ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer. The company also develops non clinical products, which includes IMC-201, a CD47xPD-L1 dual antibody based immunotherapy; and IMC-202, a PD-L1xTIGIT dual antibody based immunotherapy. The company was incorporated in 2016 and is headquartered in Yongin-si, South Korea. ImmuneOncia Therapeutics, Inc. operates as a subsidiary of Yuhan Corporation.
ImmuneOncia management
5- Mr. Heung Tae KimCEO & Inside Director · born 1956
- Mr. Donghyun YoonCFO & Executive Director · born 1971
- Mr. Sung Ho KimChief Technology Officer · born 1972
- Mr. Seyoon KimManaging Director · born 1977
- Mr. YangGyun YuManaging Director · born 1979